Predictive factors of non-sentinel axillary lymph nodes in breast cancer patients. Molecular markers of primary tumor and variability of patient's microenvironment by Goldin, Elena
 
 
 
 
 
 
 
 
TESI DI DOTTORATO 
                          
Università degli Studi di Padova 
DIPARTIMENTO DI SCIENZE CHIRURGICHE ONCOLOGICHE E GASTROENTEROLOGICHE 
 
SCUOLA DI DOTTORATO DI RICERCA IN  
ONCOLOGIA CLINICA E SPERIMENTALE E IMMUNOLOGIA 
XXX CICLO 
 
 
Predictive factors of non-sentinel axillary lymph nodes in 
breast cancer patients. Molecular markers of primary tumor 
and variability of patient's microenvironment. 
 
Tesi redatta con il contributo finanziario della Fondazione Cariparo 
 
 
 
 
Coordinatore: Ch.mo Prof.ssa Paola Zanovello  
Supervisore: Ch.mo Prof. Donato Nitti 
 
 
        
 
Dottorando: Elena Goldin  
          
 1 
INDEX 
 
 
ABSTRACT         pag. 2 
 
BACKGROUND        pag. 4  
 
- BREAST CANCER SURGERY      
- PREDICTIVE FACTORS OF AXILLARY STATUS 
- PREDICTIVE FACTORS OF AXILLARY METASTASIS 
Clinical characteristics 
Radiological characteristics 
                  Pathological characteristics 
- PREDICTORS OF NON-SENTINEL LYMPH NODES IN  
               PATIENTS WITH POSITIVE SENTINEL LYMPH NODES 
               Clinico-pathologic characteristics of primary tumor and sentinel lymph nodes 
                  Molecular markers 
                  Polymorphisms  
 
AIMS OF THE STUDY      pag. 14 
 
MATERIALS AND METHOD     pag. 15 
 
RESULTS    pag. 19 
 
- Molecular Markers      
- Polymorphisms 
 
DISCUSSION        pag. 29 
 
CONCLUSION        pag. 31 
 
BIBLIOGRAPHY        pag. 32 
 
 
 
 2 
ABSTRACT 
 
 
Background: The management of breast cancer has changed dramatically over the past two 
decades, from radical mastectomy to breast conservative surgery. Axillary lymph node dissection 
(ALND) has moved from a complete dissection to a less invasive procedure, the sentinel lymph 
node biopsy (SNLB), which has less morbidity compared to ALND and is used to evaluate lymph 
node status. Patients with positive sentinel lymph node (SNL) undergo a complete ALND of 
axillary level I and II lymph nodes. This operation is burdened by relevant postoperative morbidity, 
such as upper limb lymphedema, wound complications, nerve injury, limited mobility, neuropathic 
pain, numbness and sensory loss. Axillary lymph node metastasis in early T stage breast cancer are 
often be confined within the SNL(s), which offers no information about the presence of additional 
non-SNL (NSNL) metastasis, which may not occur in 40% to 70% of cases. The identification of 
these low risk patients would prevent them the morbidity associated with a full ALND. In order to 
avoid unnecessary, highly morbid ALND, it has become imperative for breast surgeons to find 
diagnostic tool that can identify SNL positive patients at low risk of NSNL metastasis and also who 
can safely avoid an ALND. 
 
Material and Methods: We analysed whether a panel of molecular genes, expressed in primary 
breast cancer patients who underwent SNLB for breast cancer at our Institution, could predict 
NSNL metastasis and the influence of polymorphisms of genes related to inflammatory and 
angiogenetic pathways (IL8 rs4073, VEGF-2 rs11133360) on axillary lymph node status and to 
predict NSNL metastasis.  
Molecular Markers:  
• Pilot study: We calculated the expression of a panel of genes in 24 frozen tissue samples 
from selected patients with positive SNL received ALND, 12 with negative NSNL and 12 
with positive NSNL. We customized our PCR arrays that include the genes of RT2 Profiler 
‘human modified breast cancer’ PCR arrays (SABiosciences) and 4 genes 
(NDUFA7, MERTK, FN1, PSMB6) obtained from a previous microarray study performed 
in our department (unpublished). These 88 genes are involved in tumor classification, signal 
transduction and pathways such as angiogenesis, adhesion, proteolysis, cell cycle, and 
apoptosis. 
• Validation study: We evaluated the expression of five significant genes (THBS1, IGF1, 
ERBB2, GRB7, MGMT), obtained from previous pilot experiment, in 171 frozen tissue 
samples from primary breast cancer of patient, who underwent breast surgery and SNLB for 
invasive breast cancer, between 2000 to 2013 in 1st Surgical Clinic, with RT-PCR. 
Polymorphisms (IL8 rs4073 VEGFr-2 rs11133360):  
Genomic DNA was isolated from peripheral whole blood/buffy coat of 234 patients. 10 to 20 ng of 
DNA of each patient were used for TaqMan SNP genotyping assays (Applied Biosystems). 
Genotyping was performed by Real-Time PCR using allelic discrimination in the 7300 RT-PCR 
System (Applied Biosystems). Post run data were by 7300 SDS software (Applied Biosystems) and 
Automatic calls were assigned with approximately 99.8% quality analysed. 
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Results:  
Molecular Markers: THBS1 (p:0.0012) and IGF1 (p:0,05) were statistically differently expressed 
between patients with positive SNLs and negative NSNLs and patients with positive SNLs and 
positive NSNLs. ERBB2, GRB7, MGMT were differently expressed between the two groups, not 
statistically significant (p:0,07; p:0,07; p:0,08), but we included in the validation study. The RT-
PCR for THBS1, IGF1, ERBB2, GRB7, MGMT was performed in 171 patients. Only GRB7 level 
was differently expressed in the interest group of our research. The median expression level of 
GRB7 in patients with positive SNLB and negative NSNL was 3,14 ng/ul, in the group of patients 
with positive SNL and positive ALND the median level was 6,76 ng/ul (p:0,014). The other genes 
(IGF1, MGMT, ERBB2, THBS1) had a similar expression in these groups of patients  
Vascular invasion (IV) and frozen section analysis were predictive factors of NSNLs status on 
univariate logistic regression analysis (p<0,05). Multivariate logistic regression analysis confirmed 
that GRB7 was an independent predictive factor of NSNLs in patients with positive SNLB 
(p:0,017). Moreover, frozen section analysis proved to be statistically different in the two groups on 
multivariate analysis (p:0,047).  
The discrimination of the multivariable model was assessed with the area under the receiver ROC 
curve and AUC was 0,77. 
Polymorphisms (IL8 rs4073 VEGFr-2 rs11133360): We considered two models for both 
polymorphism: dominant and recessive. When we analysed the correlation between the genotype 
and NSNLs status in patients with positive SNLs, no statistically significant results were obtained 
for both models. The two polymorphisms investigated were no predictive of axillary status in 
patients with positive SNL, but only IL8 rs4073, in recessive model, was significantly different 
between patients with axillary metastasis (N+) and patient with negative axillary status (N0) 
 
Conclusion: Our data suggest that the expression level of GRB7 could be a predictive tool of axilla 
status in patients with positive SNLB and could help the surgeon to decide the better axillary 
surgery in this group of patients. The polymorphisms investigated are not predictive of NSNL status, 
but a homozygous woman for the allele A of the polymorphism IL-8 rs4073 has a probability 2.28 
times greater than the rest of the sick population of developing axillary metastasis from breast 
cancer. 
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BACKGROUND 
 
 
BREAST CANCER SURGERY 
 
The dominant model for breast cancer in the 19th century was a mechanistic model, describing the 
disease as a local phenomenon within the breast spreading centrifugally along lymphatics to first 
and then second echelon nodes, with progressive systemic spread. Radical local surgery, the 
Halstead radical mastectomy, was a therapeutic consequence of this model. In the late 1960s, this 
model was replaced by a biological model described by Fisher1 , in which disease outcome is pre-
determined by the extent of micrometastatic dissemination, early on in the natural history of the 
disease. Depending on the assessment of recognised prognostic markers, at diagnosis, prognosis is 
now believed to be either ‘favourable’ or ‘unfavourable’ rather than disease being regarded as 
‘early’ or ‘late’. The National Surgical Adjuvant Breast Project B04 trial2 reported that axillary 
lymph node dissection was important for achieving local control and obtaining prognostic 
information, but prophylactic removal of the lymph nodes did not improve survival. This supports 
the biological model rather than the mechanical model of stepwise spread. The therapeutic 
consequence of this model has been the development of adjuvant systemic therapy using cytotoxic 
drugs or endocrine manipulation. In keeping with this model, surgical treatment of breast cancer has 
evolved substantially in the last three decades away from extensive surgical resection (radical 
mastectomy) towards a more tailored and conservative approach to the breast (lumpectomy 
followed by radiation therapy, that is the so called "breast conservation surgery"). Two randomised 
controlled trials3 4, with over 20 years of follow-up, demonstrated that breast conserving surgery 
followed by radiotherapy is as effective as mastectomy with no detrimental effect on patient 
survival. 
A comparable trend has been seen with axillary surgery, where the surgical option has evolved from 
complete ALND to SNLB, which has significantly less morbidity compared to ALND and has 
become widely used to evaluate lymph node status in patients with breast carcinoma. 
By definition, the sentinel lymph node is frequently the first node in the lymphatic basin that 
receives drainage from an anatomic region and is immunologically responsible for that region. Its 
relatively low false negative rate of 5 to 10% (patients with negative sentinel lymph node who 
developed lymph nodes metastasis during their follow-up) and high sensitivity rate of 90 to 95% in 
the detection of cancer to the lymph node basin has made this minimally invasive operation a 
standard.  
Patients with a positive SNLs undergo a complete ALND of level I and II lymph nodes. ALND is 
burdened by meaningful postoperative morbidity, such as upper limb lymphedema, wound 
complications, nerve injury, limited mobility, neuropathic pain, numbness, and sensory loss in a 
significant number of patients.  
Through aggressive screening programs and educational campaigns for patient self-exam, breast 
cancer is now detected at an earlier stage, resulting in fewer axillary metastasis, which are detected 
in 4-37% of American Joint Committee on Cancer (AJCC) TNM stage I and II.  
Although SNLB is far less morbid than ALND, it is not without risks or morbidity. It is still an 
invasive procedure and complications include pain, paraesthesia and arm swelling up to 24 months 
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after SNLB surgery5. It offers no information about the presence of additional NSNL metastasis, 
which may not occur in 40% to 70% of cases.  
 
PREDICTIVE FACTORS OF AXILLARY STATUS 
 
Recent studies have shown that axillary metastasis in early T stage breast cancer, if present, may be 
confined only to the SNLs. The identification of these low risk patients would avoid them the 
morbidity associated with a full ALND.  
In order to avoid the over-treatment suffering brought about by ALND, it has become imperative 
for breast cancer surgeons to find diagnostic tool that can identify SNL positive patients at low risk 
of NSNL metastasis and also who can safely avoid an ALND. 
It is important to make a distinction between prognostic and predictive factors6 7. Prognostic factors 
are clinical, pathologic or biological features of cancer patients that predict clinical outcome such as 
disease-free or overall survival. Predictive factors are clinical, pathologic or biological features that 
estimate the likelihood of axillary lymph node metastasis. Developments in scientific methodology 
have generated an ever-increasing number of markers for primary and metastatic disease but none 
of these are in widespread clinical use. 
Using biological parameters of the primary tumor to estimate the risk of axillary lymph node 
involvement could provide a rationale for proceeding to SNLB or axillary sampling. 
Predictors may be of particular clinical utility in cases where the SNLB is equivocal (contains 
micro-metastasis) or negative, offering a strategy to reduce the false negative rate. They may also 
offer an alternative to invasive techniques in prognostication and planning of adjuvant treatment. 
The benefit of accurate predictors of lymph node status is likely to be greatest in those patients who 
are axillary lymph node negative at the time of diagnosis, these individuals could be spared the risk, 
cost and distress of a negative axillary procedure. Predictors may also find utility in situations 
where complete lymph node sampling is not possible, for example, in the context of neo-adjuvant 
chemotherapy, which affects the ability to perform accurate surgical staging and situations where 
co-morbidity, logistical, or financial considerations prevent ALND. Ultimately, the introduction of 
these tools in clinical practice will lead to more accurate and less invasive axillary staging and 
improve breast cancer patient management and quality of life.  
Several studies have investigated these predictive factors, some groups have focused on finding 
predictive factors of axillary metastasis, while others, more recently, have studied the predictive 
factors of NSNLs in patients with positive SNLs. 
 
 
PREDICTIVE FACTORS OF AXILLARY METASTASIS 
 
Clinical characteristics 
Clinical features including young age at diagnosis, palpability of the primary tumor and axillary 
lymph nodes have been correlated with axillary lymph node status8 9. 
Clinical examination of the axilla is notoriously unreliable in detecting axillary lymph node 
involvement. Clinical characteristics are often subjective and lack the accuracy and consistency to 
guide surgical intervention, however, they may provide justification for further diagnostic tests, 
including imaging or image-guided biopsy. 
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Radiological characteristic 
Very few studies evaluated imaging of the primary tumor as a means of predicting axillary lymph 
node involvement. Santamaria et al.10 used power Doppler ultrasound to grade the vascularity of 97 
primary tumors. Number of arteries and tumor size were found to be significant independent 
predictors of lymph node status. Mussurakis et al.11, using dynamic contrast-enhanced magnetic 
resonance imaging (MRI), found that maximum enhancement ratio in regions of interest within the 
primary tumor was a strong predictor of nodal status. 
Modern imaging modalities including ultrasound (US), MRI and positron emission tomography 
(PET) have been used to image the axilla.  
With diagnostic imaging there is always a trade-off between sensitivity and specificity, depending 
on the radiological criteria used, cut-off points, inter-observer variation and patient population. 
Results to date are inconsistent with higher accuracies achieved when two imaging modalities are 
combined. With US, the reported sensitivities and specificities range from 50% to 84% and 80% to 
92%, respectively, with higher sensitivity achieved when US is combined with fine needle 
aspiration cytology (FNA)12 13 14. Two prospective studies showed moderate accuracy with FDG-
PET for the detection of axillary lymph node involvement, with a sensitivity of 61% to 85%, 
specificity of pathological characteristic	 80% to 99% and positive predictive value of 62% to 98%15 
16. FDG-PET cannot therefore be routinely recommended for axillary staging. More recently, the 
combination of US and 99mTc-sestamibi scintimammography was demonstrated to be superior to 
US alone with sensitivity, specificity and accuracy for the combination of 92%, 93% and 92%, 
respectively. 
Contrast-enhanced MRI for local staging is well established, particularly as an adjunct to determine 
suitability for breast conserving surgery and nipple preservation. There is, however, little published 
evidence on its accuracy with respect to imaging the axilla, perhaps as a result of poor contrast 
enhancement of lymph nodes with gadolinium based contrast agents used for imaging the breast. 
This may change with the use of ultra-small super paramagnetic iron oxide (USPIO) contrast agents, 
which are specifically phagocytosed by lymphocytes17.  
 
Pathological characteristics 
Tumor size 
The maximum diameter of the invasive component of the primary tumor correlates both 
qualitatively and quantitatively with axillary lymph node involvement 18, for example, in tumors of 
size <10 mm and < 20mm, 15% and 25% of cases, respectively, were found to be axillary lymph 
node positive. The seemingly simple relationship between tumor size and lymph node status is, 
however, clinically unreliable. In two studies of patients with invasive breast carcinoma, tumor size 
and peritumoral vascular invasion have emerged as the two most powerful independent predictors 
of SNL metastasis, these variables were not, however, found to be predictive of the extent of 
axillary lymph node involvement 19 20.  
 
Tumor grade and morphology  
The correlation between tumor grade and axillary lymph node involvement is well recognised21. 
The modified system of Bloom and Richardson includes a measure of cellular proliferation, 
pleomorphism and tissue differentiation. Of these three important parameters, the extent of tumor 
cell mitosis or Ki67 index (which correlates with S-phase fraction and mitotic index) is an 
independent prognostic indicator and is correlated with lymph node metastasis22 23. 
 7 
Furthermore, the proliferative index of intratumoral fibroblasts has also been shown to be associated 
with the presence of axillary lymph node involvement24. 
The histological tumor type has also been correlated with axillary lymph node involvement with 
favourable tumor types including tubular, mucinous, medullary and cribriform carcinomas20. 
 
Primary tumor extent 
The multifocality or multicentricity of the primary tumor has also been shown to be an independent 
predictor of axillary lymph node metastasis20 25. Multifocal tumors arise at different points along a 
single duct system in the same segment of the breast, whilst multicentric tumors arise from different 
duct systems in different segments of the breast. Positive resection margins may correlate with an 
aggressive phenotype, rather than inadequate surgery, and have been found to be associated with 
axillary lymph node involvement26. 
 
Tumor vascularisation 
Neo-angiogenesis is a prerequisite to tumor growth and is intimately involved with metastasis27. 
Intra-tumoral microvessel density (IMVD), evaluated with the vascular marker CD-31, has been 
identified as a surrogate marker for tumor angiogenesis and is correlated with lymph node status28. 
IMVD has been identified as an independent prognostic factor particularly for node negative 
disease29. 
 
Lymphangiogenesis 
Lymphovascular invasion of primary breast cancer has long been associated with axillary lymph 
node involvement20 30 and is defined as the presence of tumor within an endothelial celllined  space. 
Since the discovery of markers of lymphangiogenesis (including D2-40 and LYVE-1) there has 
been a growing body of evidence that correlates lymphangiogenesis with breast cancer metastasis25 
31 32. 
 
Hormone receptor status 
Progesterone receptor status as measured by nuclear immunoreactivity correlated with axillary 
lymph node involvement20 33 , but in other studies the immunohistochemical determination of 
oestrogen, progesterone or HER-2 receptor status has not been found to be consistently related to 
lymph node status25 34 35 36 
 
Molecular characteristics 
• Protein markers 
Proteins with diverse cellular functions are altered in breast cancer, some of which also correlate 
with the likelihood of lymph node metastasis. Chelouche-Lev et al.37 reported the small heat-shock 
protein alpha B-crystallin as a marker of axillary lymph node involvement in breast cancer. CD44 
(standard variant) is a cell surface adhesion molecule and CD44 negativity has been shown to be 
significantly associated with axillary node involvement38. Immunohistochemical staining of human 
breast cancer tissues with antibodies against the mucinous carcinoma associated antigen (MCA) has 
also been correlated with axillary lymph node involvement and metastasis, but analysis of the data 
did not show any association with disease-free survival39. RhoCGTPase is a novel tissue biomarker 
involved in cell polarity and motility and increased levels of this protein are associated with 
biologically aggressive breast cancers, in particular those with axillary lymph node metastasis40. 
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Expression of the enzyme Cyclo-oxygenase-2 has also been found to be associated with lymph node 
metastasis41. 
Reduced expression of both Bax and Bcl-2, which are proteins involved in the regulation of 
apoptosis, has been found to correlate with axillary metastasis42. Lectins (carbohydrate binding 
proteins) have been used to study the glycosylation of proteins and lipids on primary breast cancers. 
Staining with the lectin Helix pomatia agglutinin (HPA) has been shown to be a powerful predictor 
of axillary lymph node involvement and mortality in breast cancer43 and this relationship has been 
shown to be stronger in the context of DNA ploidy44. 
Sauer et al.45 compared the protein expression in preoperative core needle biopsy of the primary 
lesion with the protein expression in lymph nodes with sandwich immunoassays and demonstrated 
that FGF-2, Fas and TIMP-1 were predictive of nodal status (p<0.05 logistic regression).  
• Genetic markers 
Many changes in oncogenes and tumor suppressor genes have been reported in breast cancer, some 
of which correlate with lymph node metastasis and are prognostic and predictive markers46. Hirata 
et al.47 used fluorescence in situ hybridisation and found that polysomy of chromosome 7 was 
positively correlated with the number of metastatic lymph nodes and overall survival. In keeping 
with these findings, it has been reported that microsatellite instability is correlated with lymph node 
metastasis48. Kataoka et al.49 studied the transcription product of a novel human gene designated 
HRad17 in human breast cancer and found statistically significant relationships with both the 
proliferative index and lymphatic permeation of the primary tumor and lymph node metastasis. 
Grey et al.50 performed artificial neural network-based analyses of the oncogene S100A4, the tumor 
suppressor gene nm23 and steroid receptor expression (oestrogen and progesterone) and found this 
to be an effective predictor of nodal status.  
Analysis of gene expression profiles using high-throughput technologies such as microarrays has 
been used in conjunction with both non-supervised and supervised cluster analyses. The data from 
these studies show that many genes are upregulated in breast cancer and some of these correlate 
with overall survival51 52 as well as lymph node metastasis48. These analyses have yielded many 
putative predictive markers of outcome and are useful for the classification of, for example, tumor 
sensitivity to chemotherapy or radiotherapy53 54 55 56.  
Other group57 identified differential protein peaks (metal binding polypeptides at 4,871 Da and 
8,596) in primary breast cancer that predict ALN metastasis using surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).  
Other proteomic study using a combination of 2D-SDS-PAGE and Lc-MC/MS showed 19 proteins 
up-regulated and 3 proteins down-regulated in node-positive breast carcinoma compared to node-
negative breast carcinomas58.  
Hao et al. 59  tried to elucidate molecular event associated with metastatic process and with 
microarray data, observed statistically significant overexpression of IGFBP-5, down-regulation of 
cyclin D1, and unchanged MDM-2 in metastatic tumor cells. Nonetheless, although fibronectin and 
MMP2 mRNA expression levels were decreased in many metastasis specimens, expression levels of 
the corresponding proteins in the extracellular matrix were elevated in most metastasis.  
Other group did not get the same results, but observed similarities of the overall genomic and 
proteomic profiles between primary tumors and matched ALN metastasis, suggest that key 
biological characteristics of the primary breast tumor are maintained in the corresponding lymph 
node metastasis60. 
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PREDICTORS OF NON SENTINEL LYMPH NODES IN PATIENTS WITH POSITIVE 
SENTINEL LYMPH NODES 
 
Clinicopathologic characteristic of primary tumor and sentinel lymph nodes 
 
Multiple published studies have identified pathologic characteristics of the primary tumor and SNL 
that are associated with an increased likelihood of additional positive NSNLs in patients with 
positive SNLB. As shown in this table from a meta-analysis61 tumor size and metastasis size are 
most frequently find to be predictors of NSNLs (Fig.1). 
 
 
Fig 1 from Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Degnim 
AC et al. Cancer. 200361 
 
In addition to this, two most recent studies have confirmed the correlation between the size of the 
tumor and the presence of metastasis in NSNLs in positive SNLs patients62 63 . 
In the previous meta-analysis there was no correlation between the age of the patient and the 
probability of metastasis of NSNLs, whereas two recent studies have shown the opposite63 64.  
Histological grade does not seem to affect the probability of NSNLs metastasis, only two authors 
have obtained a significant correlation62-64. 
Vascular invasion confirms to be a strong predictor of not only axillary status, but also of the 
presence of additional metastasis in NSNLs, as seen from meta-analysis, but also from more current 
articles64 65 66. 
The histological type did not prove to be a good predictive factor as showed by meta-analysis61 and 
other recent studies64-66, only Nogi et al. described a statistically significant correlation between 
histotype and presence of metastasis in NSNLs. This study is retrospective with a small number of 
patients and the analysis conducted is only univariate67. 
Discordant are the results on the role of hormone receptors64, although most authors have not 
obtained correlation between expression of hormone receptors and additional metastasis in patients 
with positive SNLs63 67 68 69. Only one study showed that HER2/neu over-expression predicted the 
presence of NSNL involvement69.   
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The metastatic sentinel lymph node features are strongly related to the presence of other metastasis 
in the axilla. The main characteristics studied are: size of metastasis, presence of extranodal 
extension and number of positive SNLs61 62 66 67 70. Chae et al69 considered also the number of SNL 
removed, ratio of SNL+/SNL removed, ratio metastatic diameter/SNL diameter, area of metastasis, 
ratio metastatic area/SNL area and total metastatic area. All these parameters were predictors of 
additional metastatic disease in NSNLs (p<0,05 multivariate analysis). 
However, none of these characteristics by themselves can identify a subset of patients for whom 
ALND is unnecessary.  
Several mathematical models have been developed to predict NSNLs status in patients with breast 
cancer with SNL metastasis70 (Fig.2). These models use an array of primary tumor characteristic 
(tumor size, histologic grade, lymphovascular involvement and hormonal receptors) and nodal 
factors (number of positive SNLs, detection method and size of metastasis) to calculate the risk of 
NSNL metastasis. These include four nomograms: the Memorial Sloan-Kettering Cancer Center 
(MSKCC) nomogram, the nomogram developed by Degnim et al (Mayo nomogram), the 
nomogram developed by Pal et al (Cambridge nomogram), and the nomogram developed by Kohrt 
et al (Stanford nomogram); three scoring systems: the Tenon score, the score from The University 
of Texas M. D. Anderson Cancer Center (MDA score), and the score developed by Saidi et al (Saidi 
score), and two recursive partitioning (RP) tools developed by Kohrt. Only two models are 
available as online calculators (MSKCC and Stanford) (Fig.3). 
 
Fig.2 from Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic 
sentinel lymph nodes: a prospective multicenter study. Coutant C et al. J Clin Oncol. 2009 70. 
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Fig.3 MSKCC nomogram online 
 
Several group validated these models in retrospective study and compared the different score 
systems71 72 73 74 75 76 77 78 79. 
Coutant et al.71 evaluated and compared the tools in an independent, multicenter cohort of patients 
with breast cancer and positive SNLs. The group studied the performance of the nine models in 
terms of discrimination (AUC), calibration, FN rate, and clinical utility (number of patients at low 
risk for positive NSNLs). Only two of nine models had an AUC greater than 0.75. Three models 
were well calibrated. Two models yielded an FN rate less than 5%. Three models were able to 
assign more than a third of patients in the low-risk group. Overall, the Memorial Sloan-Kettering 
Cancer Center nomogram and Tenon score outperform other methods for all patients, including the 
subgroup of patients with only SNL micrometastasis or ITC .  
All of these studies suggest that all models do not perform equally, the routine clinical practice and 
patient characteristics varied among different hospitals, thereby, greatly influencing the accuracy, 
consistency, and reproducibility of these models and hampering their extensive application. 
 
Molecular markers 
 
Few authors have investigated the role of molecular markers in predicting the status of NSNLs. 
Several studies focused on the role of molecular subtypes classification (luminal A, luminal B, 
HER2 over-expression and triple negative) rather than on the search for real molecular markers62 64 
66. Luminal A and Luminal B relative to triple negative subgroups showed a higher risk of NSNLs 
metastasis in patients with positive SNL.  
Known et al. tried to find the biological markers of the primary tumor by immunohistochemical 
analysis: E-cadherin, CD44, cyclin D1, p21, p53, CK7, CK18, CK19, CK5, p63 did not appear to 
be helpful predictors65. 
Some authors investigated molecular markers not in primary tumor but in SNL metastasis, using 
one-step nucleic acid amplification (OSNA), to quantify total tumoral load (TTL) in the positive 
SNL68 80. This assay has been reported as a molecular detection procedure that analyses lymph node 
metastasis by detection and amplification of cytokeratin 19 mRNA. TTL was a predictor of NSNL 
 12 
additional metastasis68. 
Other authors67 investigated the role of breast cancer stem cells (CD44+CD24-) in NSNLs 
involvement. These cancer stem cells have the capacity to self renew and to differentiate, recent 
data have shown a subpopulation of this cells in the bone marrow in early breast cancer patients and 
this study demonstrated that these cells have an impact of NSNLs metastasis. Positive NSNL 
metastasis were significantly associated with CD24- expression (p:0,04), CD44+ expression 
(p:0,01) and CD44+CD24- expression (p:0,02). 
The molecular markers most studied in this field are the proteins of human matrix metalloproteases 
(MMPs). An elevated expression of MMPs and their specific inhibitors (TIMPs) by mononuclear 
inflammatory cells from the stroma (MICs) of primary tumors seems to be significantly associated 
with the evidence of distant metastasis in breast cancer81 82. These results suggest to study the 
expression of this family proteins in primary breast tumor with positive SNL and the role of MMPs 
and TIMPs as predictors of NSNLs status. MMP1 and TIMP-2 expression by MICs was 
significantly associated with metastatic spread to NSNLs. One study used to calculated the 
expression of the proteins a multiplex sandwich immunoassays and the other group an 
immunohistochemical analysis63 83. Some author84 tried to find biomarkers that can predict NSNL 
status using next-generation RNA sequencing and the table below showed the results (Fig 4).  
 
 
Fig. 4 from Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status 
prediction in breast cancer patients with metastatic sentinel lymph nodes. Liang F et al. World J Surg Oncol. 201584 
 
Molecular tests may hold significant promise, because they are more objective, more standardized, 
and easier to popularize. Unfortunately, currently available biomarkers remain limited and their 
practical value still needs additional verification. 
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Polymorphisms  
 
We know that the metastatic process does not depend only on intrinsic tumor factors, but is a result 
of interaction between the tumor and the microenvironment of the host. Particularly the pathways of 
inflammation play an important role. Numerous studies have shown how inflammatory and 
angiogenetic pathways are related to the risk of developing the tumor, but also affect its progression 
and prognosis. The balance between inflammatory and anti-inflammatory actions is essential for 
proper control of the immune response and protection against underlying tissue damage. However, 
factors such as bacterial or viral infections, diet and lifestyle exposure, as well as individual genetic 
makeup may disrupt this balance and lead to a heightened state of inflammation resulting in tissue 
damage. Interleukins (ILs) are a group of cytokines that control cell growth and differentiation, cell 
migration and inflammatory and anti-inflammatory responses of the immune system. Cytokines are 
potentially central to the carcinogenic process, since they are key regulators of immune response.  
Pro-inflammatory ILs generally include IL-1, IL-2, IL-6, IL-8, IL-15 and IL-17, whereas anti-
inflammatory ILs include IL-4 and IL-10. ILs have been linked to tumor progression. In particular, 
serum IL-8 has been shown to promote malignant progression of breast tumors and has been 
associated with inflammatory pathways and angiogenesis. IL-8 can bind to two different forms of 
the IL-8 receptor: IL-8 receptor alpha also called CXCR1 and IL-8 receptor beta also called CXCR2. 
Numerous studies investigated genetic polymorphisms in inflammatory response genes and their 
associations with breast cancer risk. NFKB1, NFKB1a, IL-8, IL-10, IL-6, IL-1a, IL1b and TNF 
polymorphisms could serve as useful predictive biomarkers for breast cancer risk85 86 87 88 89. 
Several studies showed that the polymorphism of some cytokines (IL6, IL8, IL1) are also associated 
with aggressive phenotype of breast carcinoma, as defined by the high histological grade, axillary 
lymph node metastasis and large tumor size87 88 89 90.     
Snoussi et al.90 demonstrated a significantly increased risk of breast carcinoma with heterozygous 
IL-8 (-251) TA and homozygous IL-8 (-251) AA. A significant association between IL-8 (-251) AA 
homozygous genotype and the aggressive phenotype of breast carcinoma (axillary's lymph node 
metastasis) was found90 91.  
Also the polymorphism of the IL-8 receptors (CXCR2) was associated with increased breast cancer 
risk and decreased overall survival and disease-free survival91.      
Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several 
malignancies, including breast cancer. Angiogenesis is critical for the growth and metastasis of 
invasive tumors and constitutes an important component in the suppression of cancer formation. 
The process of transporting excess nutrients, producing some risk factors, and forming tumor blood 
vessels and a route for tumor cell egress induces tumor aggression, growth, and dissemination. 
Vascular endothelial growth factor (VEGF) acts as an angiogenic inducer that is an endothelial cell-
specific mitogen, and as a mediator of vascular permeability, playing a central role in the regulation 
of this process. The vascular endothelial growth factor (VEGF) pathway has been investigated 
extensively, due to its important role in angiogenesis. The major mediator of tumor angiogenesis is 
VEGF-A, frequently referred to as VEGF, which activates the VEGF receptor-2. The VEGF gene is 
located on chromosome 6 and constitutes a highly polymorphic gene. Numerous polymorphism 
(SNPs) in the promoter, 5'- and 3'-untranslated regions (UTR) of VEGF gene have been recognized. 
This genetic variability possibly influences the production and function of VEGF. Subsequently, the 
VEGF SNPs may have an impact on breast cancer risk and disease outcome92 93. 
Patients with the −634CC genotype had significantly higher VEGF mRNA in breast cancer tissue 
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than those with −634GG or −634GC genotypes (P<0.001). High VEGF mRNA was shown to be 
associated with a tumor size >2 cm (OR:2.476; p:0.039), the presence of lymphovascular invasion 
(OR:2.406; p:0.021), and the presence of axillary nodal metastasis (OR:2.288; p:0.025)93.  
Other authors have not shown a statistically significant association between VEGF polymorphisms 
and the risk of breast cancer94 95. The most frequent polymorphism studied was +936 C/T, but  
current data on the association between VEGF +936 C/T and breast cancer susceptibility have 
shown a great discrepancy. Recent results from meta-analysis and review suggests that this 
polymorphism may not be associated with breast cancer risk96 97. 
 
 
 
AIMS OF THE STUDY 
 
Characteristics of primary tumor, such as size, grade, and hormone receptor status have been 
previously associated with NSNL involvement. Several studies identified clinical parameters and 
histo-pathological characteristics of primary tumor and its SNL metastasis that are associated with 
the risk of additional metastasis in the NSNLs. Predictive models based on retrospective analysis of 
patients’ and tumors’ characteristics (e.g., age, histological type, tumor size, lymphovascular 
invasion, and hormone receptor status), such as the Nomogram of Memorial Sloan-Kettering 
Cancer Center and the scoring systems of MD Anderson, Tenon, Cambridge, and Stanford, are the 
most frequently considered. However, the routine clinical practice and patient characteristics varied 
among different hospitals, thereby, greatly influencing the accuracy, consistency, and 
reproducibility of these models and hampering their extensive application. 
Molecular markers of primary tumor to estimate the risk of NSNL has not been studied so much. 
Breast cancer with specific gene expression or fusion have more invasive behavior and is at higher 
risk of lymph node metastasis. On the other and, neoplastic transformation, growth, invasion, and 
metastasis depend upon the establishment of a pro-angiogenic environment, which determine local 
angiogenesis together with the over-expression of pro-angiogenic and inhibitors factors.  
The main aims of this project are two: 
• investigate a panel of molecular genes expressed in primary breast cancer patients who 
underwent SNLB to predict NSNL metastasis.  
• investigate the influence of polymorphisms of genes related to inflammatory and 
angiogenetic pathways (IL8 rs4073, VEGF-2 rs11133360) on axillary lymph node status 
and to predict NSNL metastasis. 
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MATERIALS AND METHODS 
 
This research was conducted using the resources of Tissue Bank of 1st Surgical Clinic: 189 frozen 
section tissue from breast primary tumor and 234 blood/buffy coat from patients who underwent 
breast surgery for invasive breast cancer in our department between 2000 to 2016. 
 
Molecular Markers:  
• Pilot study: We calculated the expression of a panel of genes in 24 frozen tissue samples 
from selected patients with positive SNL received ALND, 12 with negative NSNL and 12 
with positive NSNL. We customized our PCR arrays that include the genes of RT2 Profiler 
‘human modified breast cancer’ PCR arrays (SABiosciences) and 4 genes 
(NDUFA7, MERTK, FN1, PSMB6) obtained from a previous microarray study performed 
in our department (unpublished). These 88 genes are involved in tumor classification, signal 
transduction and pathways such as angiogenesis, adhesion, proteolysis, cell cycle, and 
apoptosis. 
• Validation study: We evaluated the expression of five significant genes (THBS1, IGF1, 
ERBB2, GRB7, MGMT), obtained from previous pilot experiment, in 171 frozen tissue 
samples from primary breast cancer of patient who underwent breast surgery e SNL biopsy 
for invasive breast cancer (sample of population) between 2000 to 2013 in 1st Surgical 
Clinic. 
 
Laboratory techniques: 
A. RNA extraction and reverse transcription 
Each surgical specimen was snap-frozen in liquid nitrogen within 15 minutes of collection and 
stored in liquid nitrogen. Total RNA was extracted using the TRIzol reagent lysis buffer 
(Thermofisher Scientific, Waltham, MA USA) according to the manufacturer's protocol. In brief:  
1. HOMOGENIZATION  
50-100 mg of tissue were homogenized in 1 mL of TRIZOL Reagent using an homogenizer and 
5mm stainless steel beads (TissueLyser, QIAGEN, Hilden, Germany) for 2-5 min.   
2. PHASE SEPARATION 
The homogenized samples were incubated for 5 minutes at 15 - 30°C to permit the complete 
dissociation of nucleoprotein complexes. 0.2 mL of chloroform were added and samples were 
shaken vigorously for 15 seconds and incubated at 15 - 30°C for 2 to 3 minutes.  Samples were 
centrifuged at 12,000 x g for 15 minutes at 2 - 8°C. Following centrifugation, the mixture separates 
into a lower red, phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. 
RNA remains exclusively in the aqueous phase.  
3. RNA PRECIPITATION 
RNA was precipitated from the aqueous phase by mixing it with 0.5 mL isopropyl alcohol. Samples 
were incubated at 15 - 30°C for 10 minutes and then centrifuged at 12,000 x g for 10 minutes at 2 - 
8°C.  
4. RNA WASH 
The RNA pellet was washed once with 75% ethanol, adding at least 1mL of 75% ethanol. The 
samples were mixed by vortexing and centrifuged at 7,500 x g for 5 minutes at 2 - 8°C. 
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5. REDISSOLVING THE RNA 
At the end of the procedure, the RNA pellet was briefly air-dried. The RNA was dissolved in 30 µL 
RNase-free water, passing the solution a few times through a pipette tip, and incubating for 10 
minutes at 55 - 60°C.  
Quantification and quality assessment of total RNA were performed with Nanodrop 1000 
spectrophotometer (Thermofisher Scientific, Waltham, MA USA). 
A further purification step with RNeasy Mini Kit (QIAGEN, Hilden, Germany) was applied to 
RNA samples employed in the pilot study, requested for the application of the RT2 Profiler PCR 
arrays protocol (SABiosciences - QIAGEN, Hilden, Germany).  
1µg of total RNA was reverse transcribed employing MultiScribe™ Reverse Transcriptase kit 
(Thermofisher Scientific, Waltham, MA USA) following the manufacturer’s instructions. After an 
incubation of 10 minutes at 25°C, the reaction was carried out for 2 hours at 37°C and then stopped 
incubating 5 minutes at 85°C. MultiScribe™ Reverse Transcriptase is a recombinant moloney 
murine leukemia virus (rMoMuLV) reverse transcriptase that has been optimized for TaqMan-
based assays. RNA samples employed in the pilot study were reverse transcribed with RT2 First 
Strand Kit (SABiosciences - QIAGEN, Hilden, Germany). In this case the reaction was carried out 
for 15 minutes at 42°C and then stopped incubating 5 minutes at 95°C. 
B. qRT-PCR 
A real-time quantitative PCR (qRT-PCR) was performed in an LightCycler 480II (Roche Molecular 
Diagnostics Pleasanton, CA, USA) using the relative quantification method (2-ΔΔCt method) as 
previously described98. The genes were analyzed using the following TaqMan assays (Thermofisher 
Scientific, Waltham, MA USA): 
 
Hs00962908_m1 THBS1 
Hs01037698_m1 MGMT 
Hs01547656_m1 IGF1 
Hs00917999_g1 GRB7 
Hs01001580_m1 ERBB2 
Hs00187842_m1 B2M 
 
Data were analyzed with the LightCycler® 480 Instrument Software Version 1.5, adopting an 
automatically-set baseline and a fluorescence threshold adjusted to measure quantification cycle 
(Cp) values. Using the 2-ΔΔCt method the data were presented as the fold-change in gene expression 
normalized by a reference gene and relative to a calibrator sample. As the reference gene in this 
study we used Hs00187842_m1 B2M, one of the most commonly used housekeeping genes. The 
cDNA derived from the patient #191 was used as the calibrator source in our study. 
 
Polymorphisms (IL8 rs4073 VEGFr-2 rs11133360) 
We investigated these two polymorphisms in 234 patients who underwent breast surgery for breast 
cancer in our department between 2002 to 2015 and the respective blood sample, collected in our 
tissue biobank. We included in statistical analysis 188 patients, because the other patients had non 
invasive cancer (DCIS), or received neo-adjuvant treatment or we missed some data. 
 
 17 
Laboratory techniques: 
 
A. DNA extraction 
 
Genomic DNA was isolated from peripheral whole blood employing the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s instructions. 
In brief, 20 µl of QIAGEN Protease (or Proteinase K) were added to 200 µl of buffy coat. 200 µl 
Buffer AL were added to the sample and were mixed by pulse-vortexing for 15 s. The reaction was 
incubated at 56°C for 10 min. 200 µl ethanol (96–100%) were added to the sample, and were mixed 
again by pulse-vortexing for 15 s.  
The reaction mixture was applied to the QIAamp Spin Column and centrifuged at 6000 x g for 1 
min. 500 µl Buffer AW1 were added to the QIAamp Spin Column and centrifuged at 6000 x g for 1 
min. 500 µl Buffer AW2 were added to the QIAamp Spin Column and centrifuged at full speed 
(20,000 x g) for 3 min. DNA was eluted in 200 µl Buffer AE.  
Quantification and quality assessment were performed with Nanodrop 1000 spectrophotometer 
(Thermofisher Scientific, Waltham, MA USA).  
 
B. Patient genotyping 
 
Ten to 20 ng of DNA of each patient were used for TaqManSNP genotyping assays according to the 
manufacturer’s instructions (Thermofisher Scientific, Waltham, MA USA).  
The genes of interest were analyzed using the following TaqMan assays:  
 
IL8 rs4073 C__11748116_10 
VEGF-2 rs11133360 C__26111278_10 
 
Genotyping was performed by real-time PCR using allelic discrimination in the 7300 RT-PCR 
System (Thermofisher Scientific, Waltham, MA USA), using the primers provided by the 
manufacturer. PCR parameters involved an initial denaturation at 95˚C for 10 min followed by 40 
cycles at 95˚C for 15 sec and 60˚C for 1 min. Two blank (water) controls in each 96-well plate were 
used for the assay quality control. Post run data were analysed by 7300 SDS software 
(Thermofisher Scientific, Waltham, MA USA) and Automatic calls were assigned with 
approximately 99.8% quality. 
A call rate >95% was considered the cutoff to consider genotyping successful.  
 
Statistical method:  
Descriptive statistic was used to assess the frequency distribution among the study population. The 
associations between gene expression value, NSNL status, and other considered clinicopathologic 
characteristics were analyzed with chi-square test (categorical variables) and Student's T-test 
(continuous variables). Also univariate logistic regression analysis was performed. Multivariable 
logistic regression analysis was used to analyze the association of each covariate which was 
significantly associated with NSNL metastasis at univariate analysis.  
Correlation between polymorphism expression with both a recessive and a dominant model and the 
presence of metastasis in NSNLs was calculated using chi-square test.  
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The discrimination of the multivariable model was assessed with the area under the receiver 
operating characteristic curve (ROC curve, AUC). For all results two-tailed p-values <0,05 were 
considered statistically significant. 
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RESULTS 
 
Molecular Markers 
Of the 88 genes that we tested, with the pilot study, in 24 patients with positive SNLB who 
underwent lymphadenectomy, 5 genes were differently expressed in the two groups (Table 1). 
THBS1 (p:0.0012) and IGF1 (p:0,05) are statistically differently expressed between patients with 
positive SNLs and negative NSNLs and patients with positive SNL and positive NSNLs. ERBB2, 
GRB7, MGMT are not so far to be significant different expressed between the two groups (p:0,07; 
p:0,07; p:0,08) and so we included in the validation study. 
 
Table 1. Pilot study 
  THBS1 IGF1 EGFR ERBB2 GRB7 MGMT 
pz1 -2,17 -10,85 -5,58 1,27 4,38 1,53 
pz2  -1,22 1,16 1,04 1,80 1,83 1,01 
pz3 1,30 4,39 1,99 -1,10 1,46 -1,05 
pz4 -1,26 -2,79 -3,31 2,93 3,25 1,26 
pz6 -2,41 2,06 2,16 1,10 2,12 -1,02 
pz11 1,85 -1,57 -1,40 11,55 12,47 -1,48 
pz12 2,11 -1,40 -1,27 50,56 56,49 1,13 
pz17 2,06 1,45 1,78 -3,61 1,56 1,13 
pz16 1,04 -1,84 1,88 5,28 5,70 1,77 
pz19 1,56 -1,89 -2,28 4,60 4,83 2,06 
pz22 3,48 -4,99 1,11 60,55 60,13 1,69 
pz 10 1,00 1,00 1,00 1,00 1,00 1,00 
pz5 -2,16 -2,93 -2,91 -1,08 1,71 -1,07 
pz7 -1,55 -1,72 -1,35 -1,39 -1,23 1,01 
pz8 1,37 6,88 3,01 -1,16 1,48 1,10 
pz9 -2,07 1,68 2,17 -1,22 1,89 -1,01 
pz13 -2,48 4,57 2,64 -2,64 1,08 -1,23 
pz14 -1,01 1,55 -1,25 1,52 1,40 -1,39 
pz15 -1,23 1,01 1,43 1,08 -1,05 1,02 
pz18 -1,58 -1,06 2,06 2,84 4,04 -2,05 
pz20 -1,82 -1,12 -1,13 -1,19 -1,40 -1,48 
pz21 -3,70 1,25 3,82 1,82 4,48 -1,01 
pz23 -2,96 3,95 13,20 3,19 7,22 2,07 
pz24 -2,72 6,76 9,16 -4,48 -3,77 1,50 
P 0,0012 0,052 0,07 0,07 0,076 0,088 
 
In the validation study we considered frozen tissue sample from 171 patients who received breast 
surgery in 1st Surgical Clinic between 2000-2013, as a sample of population, as shown in Table 2. 
43 patients had no axillary metastasis in SNLB or in lymphadenectomy (N0), 49 had positive 
ALND (N3), but didn't receive SNLB, because the status of the axilla was already known (clinical 
positive metastatic axilla, positive fine needle aspiration from suspicious nodes) and 79 patients had 
metastasis in SNL and underwent ALND. Of these patients 53 (67%) had no metastasis in NSNLs 
(N1) and 26 (33%) had positive ALND (N2). 
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Table 2. Clinico-pathological characteristic of 171 patients  
  PZ 
TOT 
PZ N0 PZ SNL+ 
 NSNL - (N1) 
PZ SNL+  
NSNL+ (N2) 
PZ N+ 
(N3) 
Number (%)  171  43 (25,1) 53 (31) 26 (15,2) 49 (28,7) 
age  62 63,9  61,1 56,1 64,9 
size  22,4 21,1 20,8 20,9 25,9 
histotype dutt inf 138 (80,7) 35 (81,4) 40 (75,5) 21 (80,8) 43 (87,7) 
 lob inf 25 (14,6) 6 (13,9) 11 (20,7) 5 (19,2) 2 (4,1) 
 altro 8 (4,7) 2 (4,7) 2 (3,8) 0 4 (8,2) 
G 1 12 (7) 6 (14) 4 (7,5) 0 2 (4,1) 
 2 85 (49,7) 26 (60,4) 28 (52,8) 14 (53,8) 17 (34,7) 
 3 74 (43,3) 11 (25,6) 21 (39,7) 12 (46,2) 30 (61,2) 
IV yes 54 (31,6) 10 (23,2) 11 (20,7) 11 (42,3) 22 (44,9) 
 no 117 (68,4) 33 (76,8) 42 (79,3) 15 (57,7) 27 (55,1) 
MIB1-ki67  23,7 23,1 22,9 25,5 24,2 
ER neg 29 (16,9) 9 (20,9) 8 (15,1) 3 (11,5) 9 (18,4) 
 pos 142 (83,1) 34 (79,1) 45 (84,9) 23 (88,5) 40 (81,6) 
HER2 
(90 pz) 
3+ 12 (13,3) 1 (6,3) 3 (10,7) 0 8 (26,6) 
 0/1+/2+ 78 (86,7) 15 (93,7) 25 (89,3) 16 (100) 22 (73,3) 
LNF tot +  3,19 0 1,11 6,27 6,61 
LNF tot  18,65 17,48 17,87 18,92 20,38 
 
We compared each group with each other in relation to the characteristics and there was same 
difference statistically demonstrated as shown in Table 3 (chi-square for categorical variables and 
Student's T-test for continuous variables).  
The median age was 62, N2 group had the youngest age (p:0,024 N0vsN2). The median size of the 
primary tumor was 22,4mm and in case of multifocal tumors we considered the size of the largest 
tumor. As is logical the tumors with metastatic axilla (N3) had larger tumors, comparing this group 
with N1 and N0 this difference is statistically significant, there was no difference between N3 and 
N2  and between N1 and N2 (p:0,004 N0vsN3; p:0,03 NvsN3; p:0,08 N2vsN3; p:0,97 N1vsN2). 
80,7% of patients had invasive ductal carcinoma, 14,6% had invasive lobular carcinoma, the remain 
patients had other histotype (tubular, medullary, mixed). In situ carcinoma (DCIS) was excluded 
from the study. Patients with positive SNLs and negative NSNLs or positive NSNLs (N1 and N2) 
had more invasive lobular carcinoma comparing with N3 group (p:0,04 OR:0,2 chi-q:4,054 N2vs 
N3; p:0,0082 OR:0,15 chi-q: 6,99 N1vsN3). 
85 patients had moderately differentiated invasive cancer (G2), obviously in group N3 and N2 
(metastatic axilla) there were more poorly differentiated carcinomas (G3) (p:0,015 N0vsN2; 
p:0,0005 N0vsN3). 
Most of patients had no vascular invasion (IV) in the tumor (68,4%), but the presence of IV 
increased when the lymph nodes were metastatic. The patients of group N3 had more IV comparing 
with N0 and N1 group (p:0,03 OR:0,37 chi-q:4,73 N0vsN3; p:0,045 OR:0,36 chi-q:4,033 N1vsN2; 
p:0,009 OR:0,32 chi-q:6,78 N1vsN3). The vascular invasion increased as the axillary involvement 
increased.  
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The median Ki-67 of all tumor was 23,7 and most of them expressed oestrogen receptor, there were 
no difference between the four groups for both of this parameter. 
The data about Her2 expression in the tumor was incomplete, we recovered the Her2 status only in 
90 of 171 patients. The Human epidermal growth factor receptor 2 (HER2) testing was introduced 
for early breast cancer in the guidelines after 2005, before was performed only in metastatic setting, 
this dataset also includes patients received surgery before 2005. The patients with HER2 over-
expressed (3+) were 13,3% of the 90 patients, patients with positive metastatic axilla (N3) were 
Her2 3+ more frequently comparing with patients of N2 group (p:0,02 N2vsN3).     
The median number of lymph nodes removed during axillary dissection was 18,6 (range 1-40) in all 
four group. In N3 group we removed more lymph nodes comparing with N1 group (p:0.05 N1vsN3). 
Also in group N0 (patients with negative axillary status) no different numbers of lymph nodes 
(LNF) removed, because only 15 patients of group N0 received SNL biopsy without 
lymphadenectomy, the other 28 patients underwent surgery before that sentinel lymph nodes 
procedure was introduced in our surgical department (2002). 
 
Table 3. univariate analysis between all groups 
Parameter  chi-square test and Student's T-test 
age  p:0,024 N0vsN2  
size  p:0,004 N0vsN3; p:0,03 N1vs N3; p:0,08 N2vs N3; p:0,97 N1vs N2 
histotype dutt inf p:0,04 OR:0,2 chi-q:4,054 N2vs N3 
p:0,0082 OR:0,15 chi-q:6,99 N1vs N3  lob inf 
 altro 
G 1 p:0,015 N0vsN2; p:0,0005 N0vsN3 
 2 G1+G2vsG3:  
p:0,08 OR:2,49 chi-q:3,086 N0vsN2  
p:0,0006 OR:4,59 chi-q:11,77 N0vsN3 
 3 
IV yes p:0,03 OR:0,37 chi-q:4,73 N0vsN3 
p:0,045 OR:0,36 chi-q:4,033 N1vsN2                
p:0,009 OR:0,32 chi-q:6,78 N1vsN3 
 no 
HER2 3+ p:0,02  N2 vs N3 
0/1+/2+ 
LNF tot  p:0.05 N1vsN3 
 
The results of validation study for gene expression analysis are summarized in Table 4. 
 
Table 4 Gene expression in all patients, Student's T-test 
Gene expression level PZ 
TOT 
PZ N0 PZ SNL+ 
 NSNL - (N1) 
PZ SNL+  
NSNL+ (N2) 
PZ N+ 
(N3) 
p 
GRB7 (ng/ul) 8,26 6,7 3,14 6,76 15,71 p:0,014 N1vsN2 
MGMT (ng/ul) 20,6 17,14 18,52 18,38 27,1 NS 
THBS1 (ng/ul) 8,16 9,48 6,61 7,89 8,11 NS 
IGF1 (ng/ul) -8,2 -10,8 -9,14 -7,97 -5,03 0,02 N0vsN3 
ERBB2 (ng/ul) 11,3 10,1 9,36 11,48 14,26 NS 
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The RT-PCR for all selected genes was performed in 171 patients and the median level was 
8,26ng/ul for GRB7, 20,6ng/ul for MGMT, 8,16 ng/ul for THBS1, -8,2ng/ul for IGF1 and 11,3ng/ul 
for ERBB2. Gene's expression value of each group (N0-N1-N2-N3) was compared and only two 
genes were different express in the groups. The median expression level of GRB7 in patients with 
positive SNL biopsy and negative NSNL was 3,14 ng/ul, in the group of patients with positive SNL 
and positive ALND the median level was 6,76 ng/ul. This different expression was statistically 
significant with p:0,014. IGF1 level was lower in patients with negative axillary involvement (N0) 
comparing with patients with positive ALND (N3) (p:0,02).  
In the other group (N0 and N3), there was a different expression of the genes, but these difference 
was not statistically significant. 
Only GRB7 level was differently expressed in the interest group of our research (N1 and N2), the 
other genes (IGF1, MGMT, ERBB2, THBS1) had a similar expression in these groups of patients. 
 
Whereas the aim of our project is to find predictive factors of NSNLs in the patients with positive 
SNL, we focused our correlation analysis on the two groups that reflect our population of interest 
(N1-N2). The characteristics of these two group are summarized in Table 5.   
The median age was 60, the median size of tumor was 20,7mm. We performed breast conservative 
surgery in 51 patients and mastectomy in 28 patients. During the operation all patients underwent 
SNLB. The SNLs were identified by technetium-99m sulfur colloid as radioactive tracer, 
lymphoscintigraphy was performed a day before surgery and SNLs were localized with a navigator 
of the Gamma Guidance System in operating room. In 62 patients one SNL was identified, in 10 
patients 2 SNLs were found and 7 patients had 3 or more SNLs in axilla. Once localized, the SNLs 
were removed and sent to the pathology department. For frozen-section examination, nodes with 
diameters of ≤0.5 cm were bisected, while nodes measuring >0.5 cm were sectioned each 2 to 3 mm. 
For each sample, two frozen sections made at 40 µm intervals were examined. The frozen tissue 
was then thawed, fixed and embedded to obtain permanent sections. For definitive histological 
examination, two consecutive 5µm thick tissue sections were cut from a paraffin block at two levels, 
40 µm apart from each other. The sections were then stained with haematoxylin-eosin and 
immunostained with monoclonal antibody to cytokeratin. In 65 cases the surgeon asked the frozen 
section analysis, in 14 patients we sent the SNLs to the pathologist only for permanent section. In 
this situation, NSNLs were more likely to be negative (p:0,002 OR:8,13 chi-2:5,12). 
In most patients the median number of positive SNL found at pathology examination was one, in 
two patients the SNL was negative, but the pathologist found metastasis in NSNLs, these two cases 
were false negative SNL (FN).   
Most of the tumor was invasive moderately differentiated ductal carcinomas and no difference was 
reported between the patients with positive NSNLs and the patients with negative NSNLs. 
The median Ki-67 of all tumor was 23 and most of them expressed oestrogen receptor, there were 
no difference between the two groups for both of this parameter. 
We recovered the Her2 status only in 44 of 79 patients. The patients with HER2 over-expressed 
(3+) were 6,8% of the 44 patients and the HER2 expression was no statistically different between 
the two groups. 
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Table 5 Clinical-pathological characteristic and chi-square test and Student's T-test when we 
consider the interest group (SNLB positive patient N1 vs N2).  
Parameter  PZ 
TOT 
PZ SNL+ 
 NSNL - (N1) 
PZ SNL+  
NSNL+ (N2) 
p 
Number (%)  79 53 (67) 26 (33)  
age  60 61,1 56,1 NS 
size  20,7 20,8 20,9 NS 
surgery bcs 51 (64,5) 35 (66) 16 (61,5) NS 
 mastectomy 28 (45,5) 18 (44) 10 (48,5)  
histotype dutt inf 61 (77,2) 40 (75,5) 21 (80,8) NS 
 lob inf 16 (20,2) 11 (20,7) 5 (19,2)  
 altro 2 (2,6) 2 (3,8)   
G 1 4 (5,1) 4 (7,5) 0 NS 
 2 42 (53,2) 28 (52,9) 14 (53,8)  
 3 33 (41,7) 21 (39,6) 12 (46,2)  
IV yes 22 (27,9) 11 (20,7) 11 (42,3) chi-q:4,033  
p:0,045 OR:2,80 
 no 57 (72,1) 42 (79,3) 15 (57,7)  
MIB1-ki67  23 22,9 25,5 NS 
ER neg 11 (13,9) 8 (15,1) 3 (11,5) NS 
 pos 68 (86,1) 45 (84,9) 23 (88,5)  
HER2 
(44 pz) 
3+ 3 (6,8) 3 (10,7) 0 NS 
 0/1+/2+ 41 (93,2) 25 (89,3) 16 (100)  
GRB7 (ng/ul)  4,24 3,14 6,76 p:0,014 
MGMT (ng/ul)  18,42 18,52 18,38 NS 
THBS1 (ng/ul)  7,47 6,61 7,89 NS 
IGF1 (ng/ul)  8,89 -9,14 -7,97 NS 
ERBB (ng/ul)  9,32 9,36 11,48 NS 
frozen section yes 65 (82,3) 40 (75,5) 25 (96,1) chi-Q:5,12  
p:0,002 OR:8,13 
 no 14 (17,7) 13 (24,5) 1 (3,9)  
n° SNL  1 62 (78,5) 40 (75,5) 22 (84,6)  
 2 10 (12,6) 7 (13,2) 3 (11,5) NS 
 >3 7 (8,9) 6 (11,3) 1 (3,9)  
n° SNL - 0 58 38 20 NS 
 1 15 9 6  
 >2 7 6 1  
n° SNL + 0 (FN) 2 (2,5) 2 (3,8) 0 NS 
 1 68 (86,1) 46 (86,8) 22 (84,7)  
 2 5 (6,3) 4 (7,5) 1 (3,8)  
 3 4 (5,1) 1 (1,9) 3 (11,5)  
Size SNL meta  micro 8 (10,1) 8 (15,1) 0 chi-Q:3,94  
p:0,047 OR:44,27 
 macro 71 (89,9) 45 (84,9) 26 (100)  
LNF tot  18,06 17,87 18,92 NS 
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Patients with positive SNLs and presence of IV had higher probability to have positive NSNL 
(p:0,045 OR:2,80 chi-q:4,033), this result was already demonstrated by numerous studies64 65 66. 
All patients with positive NSNLs had macrometastatic involvement of SNLs, the size of metastasis 
in SNL was a good predictive factors on NSNL status (p:0,047), as a lot of studies shown 61 62 66 67 70.  
In presence of SNLs' micrometastasis there was lower probability to have other axilla metastasis, 
the actual guidelines (AIOM, NCCN) suggest to avoid ALND in these case, based on results from 
important trial99. The patients considered in these studies underwent surgery when these guidelines 
were not yet updated, and we performed ALND, also when SNLs were micrometastatic.     
We removed the same number of SNLs in the two groups and there were no difference in positive 
or negative number of SNLs between the two groups (p>0,05). 
We performed also univariate logistic regression analysis for all variables in patients with positive 
SNLB. The results of these statistical analysis confirmed the predictive value of GRB7, frozen 
section analysis and vascular invasion, as shown in Table 6. Diameter of metastasis was not 
confirmed to be statistically significant different between the two group at univariate logistic 
regression, probably for the small number of events (only 16 patients with micrometastasis). 
 
Table 6. Univariate logistic regression analysis 
--------------------------------------------------------------------------------------------- 
          axilla    | Odds Ratio   Std. Err.       z            P>|z|      [95% Conf. Interval] 
--------------------------------------------------------------------------------------------- 
              grb7 |   1.118091   .0510541     2.44      0.015       1.022374    1.222769 
                  IV|   2.733333   1.427824     1.92      0.054       .9818534    7.609192 
frozen section|   8.333333   8.907565     1.98      0.047       1.025564    67.71343 
---------------------------------------------------------------------------------------------  
 
Multivariate logistic regression analysis confirmed that GRB7 level was an independent predictive 
factor of NSNLs in patients with positive SNLB. Also frozen section analysis was statistically 
different in the two groups at multivariate analysis (Table 7). 
 
Table 7. Multivariate logistic regression 
-------------------------------------------------------------------------------------------------- 
                       | Odds Ratio   Std. Err.      z           P>|z|       [95% Conf. Interval] 
-------------------------------------------------------------------------------------------------- 
               grb7 |   1.116578   .0516715     2.38      0.017      1.01976    1.222587 
frozen section |   8.664052    9.41185     1.99       0.047      1.03051    72.84338 
                  IV |   2.560662   1.467849     1.64      0.101     .8325644    7.875657 
--------------------------------------------------------------------------------------------------- 
 
We calculated the Receiver operating characteristic (ROC) curves for our predictive factors at 
univariate logistic regression analysis (GRB7 level, IV and frozen section analysis) as shown in 
Fig.5.  
Discrimination of multivariable model was quantified with the area under the receiver operating 
characteristic (ROC) curve (AUC), and the AUC was 0,77. 
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Fig.5 ROC curves for our predictive factors (GRB7 level, IV, frozen section) of NSNL status in patients with positive 
SNLB 
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RESULTS 
 
 
 
Polymorphisms 
We analysed the results of genotyping for IL8 rs4073 and VEGF-2 rs11133360 of 188 patients from 
234 blood samples of patients who underwent breast surgery in our Surgical Unit between 2002-
2015. The characteristics of the patients are shown in Table 8. 
46 patients were eliminated from the analysis because the data were incomplete or patients received 
neo-adjuvant chemotherapy (22). All of 188 underwent surgical axillary staging. 96 patients had no 
metastasis invasion in SNLs, 27 patients received ALND that was positive, without SNLB, because 
the status of axilla was already known before surgery (clinical positive metastatic axilla, positive 
fine needle aspiration from suspicious nodes). 65 patients had positive SNLs, 42 (64,5%) had 
negative NSNLs after lymphadenectomy, 23 (35,5%) had positive ALND.       
 
Table 8. Clinico-pathological characteristic patients genotyping for polymorphisms 
  PZ 
TOT 
PZ N0 PZ SNL+ 
 NSNL - (N1) 
PZ SNL+  
NSNL+ (N2) 
PZ 
N+ 
  188 96 42 23 27 
age  61,2 60,9 63 56,8 63,2 
size(mm)  20,5 20,4 20,8 20,6 28,3 
histotype dutt inf 147 76 30 17 23 
 lob inf 22 6 8 6 2 
 ca i.d.  7 7    
 altro 10 5 3 0 2 
G 1 20 12 5 0 3 
 2 100 61 22 11 6 
 3 68 23 15 12 18 
IV yes 149 82 36 15 16 
 no 39 14 6 8 11 
ki67  20,6 18,6 20,7 22,6 26,1 
ER neg 44 23 8 5 8 
 pos 144 73 34 18 19 
LNF tot +  2,14 0 1,12 6,7 7,4 
LNF tot  13,4 7,9 17,3 17,8 23,3 
 
We considered two models for both polymorphism: dominant and recessive. The stratification of 
patients, according to genotypes of IL8 rs4073 and VEGF-2 rs11133360 gene polymorphism are 
summarized in figure 6.   
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Fig.6 stratification of patients according to genotypes 
 
When we analysed the correlation between the genotype and NSNLs status in patients with positive 
SNLs, no statistically significant results were obtained for both models (Fig. 7-8).  
The two polymorphisms investigated were no predictive of axillary status in patients with positive 
SNL (Fig.7-8), but only IL8 polymorphism in recessive model was significantly different between 
patients with axillary metastasis (N+) and patient with negative axillary status (N0) (Fig.9).   
 
 
p:0.9                                                                        p:0.67 
Fig 7 Correlation between recessive and dominant polymorphism IL-8 rs 4073 and NSNLs status 
 
 
p: 0.67                                                                    p:0.98                                                    
Fig.8 Correlation between recessive and dominant polymorphism VEGF rs 11133360 and NSNLs status 
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p:0.0024 OR:2,28 chi-q:9,19 
Fig. 9 Correlation between recessive polymorphism IL8 rs 4073 and axillary status  
 
In other words, a homozygous woman for the allele A of the polymorphism IL-8 rs4073 has a 
probability of 2.28 times greater than the rest of the sick population of developing axillary 
metastasis from breast cancer. These results were already demonstrated by other groups90 91. 
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DISCUSSION 
 
 
Our data suggest that GRB7 could be an independent predictive marker of NSNLs status in patients 
with positive SNLB. No other genes demonstrated the same predictive role.  
This result was very important, because the level of GRB7 was demonstrated statistically significant 
different with all statistical tests used (p:0,014 t-Student; p:0,015 univariate logistic regression; 
p:0,017 multivariate logistic regression), confirming the predictive role of this test.  
This result could be explained by the biological role of GRB7. GRB7 is an adaptor molecule 
mediating signal transduction from multiple cell surface receptors to diverse downstream 
pathways100. GRB7, along with Grb10 and Grb14, make up the Grb7 protein family. This protein 
family has been shown to be over-expressed in certain cancers and in cancer cell lines101 102. Grb7 
over-expression has been linked to enhanced cell migration and metastasis, has been implicated as a 
downstream mediator of integrin- FAK signal pathways in the regulation of cell migration, although 
the molecular mechanisms are still not well understood103. Other authors showed that high Grb7 
expression was strongly associated with decreased survival in all patients and in the node positive 
subset (p:0.0034 and p:0.0019). In this study on multivariable analysis, it remained an independent 
prognostic marker (p:0.01)104. 
The important role of GRB7 as prognostic marker is demonstrated by the fact that this gene is one 
of 21 genes included in Oncotype DX105.   
Higher GRB7 level probably increase the attitude of cancer cell to migration and explain the higher 
invasion of NSNLs in patient with positive ALND. 
In our series the level of GRB7 was calculated in all patients (171) and was compared between all 
the 4 groups, that represented all possible scenario in the axilla, as a sample of population. The 
Group N0 that are patients without axillary metastasis are not representative of population, are only 
43 patients, 25% of our series. The actual population underwent axillary dissection has a higher 
probability of negative SNLB, thanks to screening programs. Our series probably has this low 
number of non-metastatic patients because most patients underwent surgery between 2000 to 2006, 
when early diagnosis was less common and also we started to introduced SNLs biopsy. Our bank 
has predominantly palpable tumors as we can see from the medium size of the tumors (22mm), 
because there was agreement with the pathologist to pick up the tissue for bio bank only in medium 
size tumors, during the surgical operation. We were not allowed to take a sample of small tumor in 
order not affect the histological diagnosis. In the future we will try to solve this problem by taking 
the sample of no palpable lesions, the smaller ones, for biobank, during the diagnostic biopsies, 
often performed by radiologists.  
The groups N1 and N2 are more representative of the current population, 67% of patients with 
positive SNLs had negative NSNLs and 33% had positive NSNLs, as reported in numerous 
studies61-80.          
In our study some clinical-pathologic characteristics seem to be a good predictive factors of NSNLs 
status: IV and frozen section analysis, confirmed also on univariate logistic regression analysis.  
A lot of studies had already demonstrated that vascular invasion is a predictive factor of axillary 
staging20-30 and also increased the risk of NSNL metastasis in patient with positive SNLs64-66. The 
vascular invasion is one of the pathologic characteristic of tumor included in Nomogram of 
Memorial Sloan-Kettering Cancer Center and in scoring systems of MD Anderson70-79. 
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The patients received frozen section analysis of positive SNLs had 8.8 times greater then patients 
received routine SNLs histologic examination of having metastasis in NSNLs (chi-Q:5,12 p:0,002 
OR:8,13; p:0,046 multivariate logistic regression). This finding could be explained by the fact that 
the surgeon asks for the frozen section analysis, when he thinks there is a good chance that lymph 
node will be positive based on the characteristics of primitive tumor, or because during the biopsy 
procedure SNLs has suspected macroscopic characteristics. The surgeon requests an intra-operative 
assessment to pathologist, when probably a ALND is necessary to avoid a second surgical 
procedure to the patients. 
The size of metastasis in SNLs has an important role in predicting the NSNLs status: in our series 
no micrometastasis (size of metastasis 0,2mm ≤2mm) were found in SNLs of patients with positive 
NSNLs, confirmed the predictive power (p:0,047 Student's T-test). This result was not confirmed 
on logistic regression analysis and multivariate logistic regression analysis, probably for small size 
of our series. Regardless of this result, the current guidelines99 do not indicate the need for ALND 
in patients with micrometastasis in SNLs. 
The discrimination of the multivariable model was assessed with the area under the receiver 
operating characteristic curve ROC (Fig.5) and illustrated the high diagnostic ability of our 
predictive test. The current nomograms71 have lower AUC comparing with AUC of 0,77, as 
reported in our series.  
In this study the correlation between molecular subtype (luminal A, luminal B, HER2 over-
expression and triple negative) was not done because the lack of information about HER2 test. 
The second part of this study investigated the role of IL-8 and VEGF polymorphisms to predict the 
NSNLs status in patients with positive SNLs. We knew from the literature89-91 that IL8 rs 4073 
polymorphism increased the risk of developing breast cancer and influenced prognosis, promoting 
greater axillary involvement. That is why we wanted to understand whether this polymorphism 
could also increase the risk of positivity of NSNLs in positive SNLs patients. As shown before this 
polymorphism not influenced the NSNLs status (Fig.7-8). Our results confirmed only the literature 
data that patients homozygous for the allele A of the polymorphism IL-8 rs4073 has metastasis in 
axillary lymph nodes greater than the rest of the sick population. VEGF polymorphism was 
demonstrated not to correlate with breast cancer aggressiveness.  
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CONCLUSION 
 
This study suggests that the surgeon could use the expression level of GRB7 as a predictive tool of 
axilla status in patients with positive SNLB and this test could help the surgeon to define better 
axillary surgery approach in this group of patients. 
On the other hand, some limitations still exist in the present study: all data result from retrospective 
analysis and the population with positive SNL is small in number. We need to validate these results 
in a larger population and in a prospective study. The other limit is that the level of GRB7 was 
tested in frozen tissue, that was accurate, but only few hospitals have a tissue bank, so this test was 
not accessible and hampering extensive application. Further investigations are required to determine 
whether this result will can be successfully translated to paraffin-embedded tissue. 
Our outcomes suggest that molecular markers could be a good predictive factors of NSNLs in 
positive SNLs patients and is necessary to extend the research to more genes, in order to create a 
genomic test (such as Oncotype DX) predictive of NSNLs status. 
In the era of AMAROS trial106 and ACOSOG Z0011107, finding predictive marker of NSNLs with 
high accuracy, sensibility and sensitivity will be very important, to improve the current surgical 
practice in staging the axilla, aiming to precision medicine for less invasive treatment for patients. 
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